PL2968346T3 - Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego - Google Patents

Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego

Info

Publication number
PL2968346T3
PL2968346T3 PL14763483.6T PL14763483T PL2968346T3 PL 2968346 T3 PL2968346 T3 PL 2968346T3 PL 14763483 T PL14763483 T PL 14763483T PL 2968346 T3 PL2968346 T3 PL 2968346T3
Authority
PL
Poland
Prior art keywords
gamma
modulation
compositions
methods
glutamyl cycle
Prior art date
Application number
PL14763483.6T
Other languages
English (en)
Inventor
David Rubin
Eyal Rubin
Original Assignee
Cancer Research Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technologies Llc filed Critical Cancer Research Technologies Llc
Publication of PL2968346T3 publication Critical patent/PL2968346T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14763483.6T 2013-03-15 2014-03-15 Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego PL2968346T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801709P 2013-03-15 2013-03-15
PCT/US2014/030053 WO2014145314A2 (en) 2013-03-15 2014-03-15 Methods and compositions for gamma-glutamyl cycle modulation

Publications (1)

Publication Number Publication Date
PL2968346T3 true PL2968346T3 (pl) 2024-11-04

Family

ID=51529989

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14763483.6T PL2968346T3 (pl) 2013-03-15 2014-03-15 Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego

Country Status (14)

Country Link
US (4) US9630936B2 (pl)
EP (1) EP2968346B1 (pl)
JP (2) JP6458000B2 (pl)
KR (2) KR102707287B1 (pl)
CN (1) CN105246483A (pl)
AU (2) AU2014233168B2 (pl)
CA (2) CA2909510C (pl)
DK (1) DK2968346T3 (pl)
EA (1) EA030611B1 (pl)
ES (1) ES2977144T3 (pl)
FI (1) FI2968346T3 (pl)
IL (2) IL283717B (pl)
PL (1) PL2968346T3 (pl)
WO (1) WO2014145314A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968346T3 (pl) 2013-03-15 2024-11-04 Cancer Research Technologies Llc Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego
JP6570512B2 (ja) 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤
WO2016109002A2 (en) * 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN107382903B (zh) * 2017-05-22 2021-02-26 重庆南松凯博生物制药有限公司 一种抗癌药物中间体的制备方法
US20230107538A1 (en) * 2019-12-19 2023-04-06 Liminal Biosciences Limited Cycloalkyl-containing carboxylic acids and uses thereof
WO2022174062A1 (en) * 2021-02-12 2022-08-18 Recovery Therapeutics, Inc. Methods and compositions for modulating fgf activity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4011233A (en) 1973-06-28 1977-03-08 Givaudan Corporation 2-methyl-2-(4-methyl-3-pentene-1-yl) thiazolidine
JPS56133216A (en) * 1980-03-24 1981-10-19 Senjiyu Seiyaku Kk Antitumor agent
JPS57128625A (en) * 1981-01-30 1982-08-10 Rikagaku Kenkyusho Carcinostatic
DE3586683T2 (de) * 1984-12-18 1993-04-08 Clark Pharma Dev Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln.
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
JP2717257B2 (ja) * 1988-03-19 1998-02-18 参天製薬株式会社 光学活性化合物の製造法
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
NL9001955A (nl) * 1990-09-05 1992-04-01 Cedona Pharm Bv Nieuwe thiazolidinederivaten.
US7425635B2 (en) * 1997-08-07 2008-09-16 University Of Utah Research Foundation Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
WO2003082268A2 (en) 2002-03-22 2003-10-09 Eisai Co. Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
CA2541667A1 (en) 2003-10-14 2005-04-21 Pharmacia Corporation Substituted pyrazinone compounds for the treatment of inflammation
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20060014740A1 (en) * 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
EA200600992A1 (ru) * 2003-11-18 2006-10-27 Юниверсити Оф Теннесси Рисерч Фаундейшн Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
CA2548391A1 (en) * 2003-12-18 2005-06-30 Zoser B. Salama Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
BRPI0507612A (pt) * 2004-02-11 2007-07-03 Univ Ohio State Res Found análogos exibindo inibição de proliferação de célula e métodos para fabricação e uso destes
KR20060014740A (ko) 2004-08-12 2006-02-16 조정래 항균 수처리기
US7702430B2 (en) * 2004-11-19 2010-04-20 The Board Of Regents Of The University Of Texas System Method for designing a potential inhibitor of glutathione-aldehyde conjugate binding to aldose reductase
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
JP4446922B2 (ja) 2005-04-21 2010-04-07 富士通メディアデバイス株式会社 フィルタおよび分波器
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2007139573A1 (en) * 2006-05-31 2007-12-06 The Trustees Of Columbia University In The City Of New York Ribosome and rna display of biologically active small molecules
US20090233972A1 (en) * 2008-03-12 2009-09-17 Yat Sun Or Substituted heterocycles as anti-infectives
KR100935543B1 (ko) 2008-04-02 2010-01-07 (주)예기산업 자연순환방식의 프리히팅장치 및 이를 이용한프리히팅시스템
WO2009154562A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
PL2475428T3 (pl) * 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
KR20110092501A (ko) 2010-02-09 2011-08-18 주식회사 캐러스 하이브리드 항균 펩타이드 및 이의 용도
KR101395146B1 (ko) * 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
JP2015522531A (ja) * 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
PL2968346T3 (pl) * 2013-03-15 2024-11-04 Cancer Research Technologies Llc Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego

Also Published As

Publication number Publication date
KR20160003652A (ko) 2016-01-11
CN105246483A (zh) 2016-01-13
WO2014145314A3 (en) 2014-11-13
EA030611B1 (ru) 2018-08-31
AU2014233168A1 (en) 2015-11-05
IL283717A (en) 2021-07-29
EP2968346B1 (en) 2024-02-07
AU2014233168B2 (en) 2018-11-22
JP6739509B2 (ja) 2020-08-12
US9630936B2 (en) 2017-04-25
US20170226070A1 (en) 2017-08-10
IL283717B (en) 2022-09-01
CA2909510C (en) 2024-04-02
FI2968346T3 (fi) 2024-05-06
US11186555B2 (en) 2021-11-30
CA2909510A1 (en) 2014-09-18
US20190359580A1 (en) 2019-11-28
ES2977144T3 (es) 2024-08-19
KR102707287B1 (ko) 2024-09-20
AU2019201264B2 (en) 2020-07-16
US12686667B2 (en) 2026-07-21
JP2016515531A (ja) 2016-05-30
DK2968346T3 (da) 2024-05-06
JP2019065031A (ja) 2019-04-25
US20140275187A1 (en) 2014-09-18
JP6458000B2 (ja) 2019-01-23
US20220324820A1 (en) 2022-10-13
WO2014145314A2 (en) 2014-09-18
US10323009B2 (en) 2019-06-18
CA3232320A1 (en) 2014-09-18
EA201500941A1 (ru) 2016-07-29
KR20210144942A (ko) 2021-11-30
EP2968346A2 (en) 2016-01-20
IL241620B (en) 2021-06-30
EP2968346A4 (en) 2017-02-08
AU2019201264A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
IL282202A (en) Compositions and methods for personalized neoplasia vaccines
IL283660A (en) Compositions and methods for modulating apolipoprotein (a) expression
PL2981822T4 (pl) Kompozycje i sposoby modulacji czynnika wzrostu
IL241112B (en) Methods and compositions for modification of hla
HRP20180817T1 (hr) Sastavi i postupci za modulaciju farnesoid-x-receptora
IL243043B (en) Dynamic modification of modulation throughout a therapy period
IL244388A0 (en) Cyclic peptidomimetic compounds as immunomodulators
IL240388A0 (en) Methods of treating melanoma
EP2953474A4 (en) COMPOSITIONS AND METHODS
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
EP2889350A4 (en) ADHESIVE COMPOSITION
DK3027750T3 (da) Biokatalytisk sammensætning
DK2992104T3 (da) Fremgangsmåde til ekspression
EP3039131C0 (en) ENZYME COMPOSITION AND USES
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
IL283717A (en) Methods and compositions for gamma-glutamyl cycle modulation
DK2956410T3 (da) Kompositsilicium- eller komposittinpartikler
HUE046723T2 (hu) Töltõanyag-készítmény lipoatrófia kezelésére
FR3001759B1 (fr) Rouge aubagee de turbomachine
EP3037112A4 (en) PROSTHESIS
HRP20181307T1 (hr) Postupak izrade zubne proteze
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder